



## 1. Company details

<b>Name of entity:</b>	Kazia Therapeutics Limited
<b>ABN:</b>	37 063 259 754
<b>Reporting period:</b>	For the year ended 30 June 2022
<b>Previous period:</b>	For the year ended 30 June 2021

## 2. Results for announcement to the market

					\$
Revenues from ordinary activities	down	100.0%	to		-
Loss from ordinary activities after tax attributable to the owners of Kazia Therapeutics Limited	up	192.7%	to	(24,647,815)	
Loss for the year attributable to the owners of Kazia Therapeutics Limited	up	192.7%	to	(24,647,815)	

### Dividends

There were no dividends paid, recommended or declared during the current financial period.

### Comments

The loss for the consolidated entity after providing for income tax amounted to \$24,647,815 (30 June 2021: \$8,421,960).

## 3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	(1.02)	12.01

## 4. Control gained over entities

Not applicable.

## 5. Loss of control over entities

Not applicable.

## 6. Dividends

### Current period

There were no dividends paid, recommended or declared during the current financial period.

### Previous period

There were no dividends paid, recommended or declared during the previous financial period.

## 7. Dividend reinvestment plans

Not applicable.

## 8. Details of associates and joint venture entities

Not applicable.

## 9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

## 10. Audit qualification or review

### Details of audit/review dispute or qualification (if any):

The financial statements have been audited and an unqualified opinion has been issued.

## 11. Attachments

### Details of attachments (if any):

The Directors' report and financial statements of Kazia Therapeutics Limited for the year ended 30 June 2022 is attached.

## 12. Signed



---

Mr Iain Ross

Chairman

Date: 29 August 2022